Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT

[1]  F. Prinzen,et al.  Why QRS Duration Should Be Replaced by Better Measures of Electrical Activation to Improve Patient Selection for Cardiac Resynchronization Therapy , 2016, Journal of Cardiovascular Translational Research.

[2]  James E. Helmreich.  Regression Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression and Survival Analysis (2nd Edition) , 2016 .

[3]  L. Mestroni,et al.  Improving the appropriateness of sudden arrhythmic death primary prevention by implantable cardioverter-defibrillator therapy in patients with low left ventricular ejection fraction. Point of view , 2016, Journal of cardiovascular medicine.

[4]  A. Moss,et al.  Lessons learned from the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). , 2016, Trends in cardiovascular medicine.

[5]  J. Januzzi,et al.  ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. , 2015, The American journal of cardiology.

[6]  Thomas J. Wang,et al.  Soluble ST2 testing in the general population. , 2015, The American journal of cardiology.

[7]  Jagmeet P. Singh,et al.  Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy , 2015, Journal of Interventional Cardiac Electrophysiology.

[8]  W. Kraus,et al.  Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. , 2014, JACC. Heart failure.

[9]  J. Cohn,et al.  Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial , 2014, Circulation. Heart failure.

[10]  Thomas J. Wang,et al.  Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. , 2014, JACC. Heart failure.

[11]  W. Kraus,et al.  Soluble ST2 in Ambulatory Patients With Heart Failure: Association With Functional Capacity and Long-Term Outcomes , 2013, Circulation. Heart failure.

[12]  F. Spinale,et al.  Biomarkers and Heart Disease: What is Translational Success? , 2013, Journal of Cardiovascular Translational Research.

[13]  J. Januzzi.  ST2 as a Cardiovascular Risk Biomarker: From the Bench to the Bedside , 2013, Journal of Cardiovascular Translational Research.

[14]  P. Neužil,et al.  Short term effect of CRT on biomarkers of cardiac remodelling and fibrosis: NT-proBNP, sST2, galectin-3, and a marker of oxidative stress--ceruloplasmin--a pilot study. , 2012, International journal of cardiology.

[15]  J. McMurray,et al.  Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology , 2012, European journal of heart failure.

[16]  J. Lupón,et al.  Combined use of high‐sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure , 2012, European journal of heart failure.

[17]  H. Uno,et al.  Dyssynchrony, Contractile Function, and Response to Cardiac Resynchronization Therapy , 2011, Circulation. Heart failure.

[18]  A. Wu,et al.  High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.

[19]  M. Gold,et al.  Risk stratification of ventricular arrhythmias in patients with systolic heart failure , 2010, Current opinion in cardiology.

[20]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[21]  Juan Cinca,et al.  Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. , 2009, Journal of the American College of Cardiology.

[22]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[23]  Wojciech Zareba,et al.  Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT‐CRT): Design and Clinical Protocol , 2005, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[24]  T. Rea,et al.  Incidence of out-of-hospital cardiac arrest. , 2004, The American journal of cardiology.

[25]  Expression and Regulation of ST 2 , an Interleukin-1 Receptor Family Member , in Cardiomyocytes and Myocardial Infarction , 2002 .